ArticleDiabetes care2012
Pioglitazone and bladder cancer: a population-based study of Taiwanese.
Article in Diabetes care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 6 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.Cancer medicine · 2018Pooled it
- Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis.Archives of gynecology and obstetrics · 2017Pooled it
- Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.British journal of clinical pharmacology · 2014Pooled it
- Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis.The oncologist · 2013Pooled it
- Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2012Pooled it
- Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort).BMC dermatology · 2016Trial
- Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system.European journal of clinical pharmacology · 2024Article
- Cancer biology in diabetes update: Focusing on antidiabetic drugs.Journal of diabetes investigation · 2024Review
- Article
- SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives.Cancers · 2022Review
- Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.BMC cancer · 2022Article
- Insulin Resistance and Cancer: In Search for a Causal Link.International journal of molecular sciences · 2021Review
- Type 2 Diabetic Sepsis Patients Have a Lower Mortality Rate in Pioglitazone Use: A Nationwide 15-Year Propensity Score Matching Observational Study in Taiwan.Emergency medicine international · 2021Article
- Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.Diabetes, obesity & metabolism · 2019Article
- Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies.Diabetology international · 2019Article
- High Glucose with Insulin Induces Cell Cycle Progression and Activation of Oncogenic Signaling of Bladder Epithelial Cells Cotreated with Metformin and Pioglitazone.Journal of diabetes research · 2019Article
- Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus.Annals of vascular diseases · 2018Review
- Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.Diabetes, obesity & metabolism · 2018Article
- Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis.Cancer management and research · 2018Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe association between pioglitazone and bladder cancer has not been investigated in Asians. We aimed to investigate this association. RESEARCH DESIGN AND
methodsA total of 1,000,000 individuals were randomly sampled from the National Health Insurance database, and incident cases of bladder cancer during the period from 1 January 2006 to 31 December 2009 were analyzed among 54,928 patients with type 2 diabetes and without previous bladder cancer.
resultsAmong 165 incident case subjects, 10 (0.39%) were ever users and 155 (0.30%) were never users of pioglitazone (adjusted hazard ratio in full model 1.305 [95% CI 0.661-2.576]). All bladder cancer in ever users occurred within a duration of therapy <24 months, suggesting an early effect of pioglitazone on bladder cancer or late use of pioglitazone in high-risk patients.
conclusionsThe association between pioglitazone and bladder cancer was not significant. However, confirmation of this finding is required because of the possible lack of statistical power owing to the small number of events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.